anti muc21 antibody  (Novus Biologicals)

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: MUC21 Expression by analyzing high-throughput dataset including Affymetrix GeneChip ® Human Transcriptome Array 2.0(HTA), GSE34105 from GEO and TCGA RNAseq data. (A-F) , the heatmaps of hierarchical clustering and volcano plots of differential gene expressions revealed by HTA based on 10 paired OSCC and adjacent normal oral tissue; GSE34105 based on 62 OSCC and 16 normal oral tissue; TCGA base on 266 OSCC and 19 normal oral tissue. Genes with a fold change >2 and adj-P-value of <0.05 were highlighted. (G, H) the up and down regulated genes in the three datasets were intersected and it was showed that 73 was up and 102 were down regulated in the intersection which comprised only MUC15 and MUC21 from Mucin family. (I) relative expression level (the median of the three datasets) comparison showed that MUC21 was more down regulated than MUC15, the chart was created from Excel (Microsoft ® for Excel). OSCC, oral squamous cell carcinoma.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing, High Throughput Screening Assay, RNA sequencing, Comparison

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: MUC21 co expression gene analysis by cor.test of R language in the TCGA. (A-K) , the correlation analysis of MUC21 to SPRR3, MAL, TMPRSS11B, CAPN14, FUT6, CEACAM7, CRNN, DYNAP, IL36A, KRT13, KRT4. R value was set at more than 0.7, and P value was set less than 0.001. (L) , Top five negatively or positively correlated genes were showed in circos map.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: Quantitative qRT-PCR and immunohistochemistry analysis of MUC21, KRT4, KRT13, and CRNN in OSCC and para-OSCC. (A-D) showed that MUC21, KRT4, KRT13 and CRNN were down regulated in OSCC than para-OSCC (P< 0.0001), the expression levels were normalized against GAPDH. (E) Spearman correlation analysis showed that MUC21was related with KRT4, KRT13 and CRNN at mRNA level. (F-I) showed that MUC21 and KRT4 were down regulated in OSCC than para-OSCC (P<0.0001); KRT13 was down regulated in OSCC than para-OSCC (P <0.05); and CRNN was also down regulated in OSCC than para-OSCC (P<0.001). (J) Spearman correlation analysis showed that MUC21 was related with KRT4, KRT13 and CRNN at protein level too.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Quantitative RT-PCR, Immunohistochemistry, Expressing

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: MUC21 expression analysis in OSCC and para-OSCC via immunohistochemistry (IHC) and its relation with critical clinical characters. (A) a whole block of OSCC and para-OSCC tissue analyzed by IHC showed that MUC21 was expressed in para-OSCC epithelium and lost in OSCC. (B) MUC21 expression between OSCC and para-OSCC in 102 paired patient samples was quantified by mean optical density (MOD) values. MUC21 decreased significantly in OSCC (P < 0.0001). Box plots represent the median, 25th, and 75th percentiles of the data. (C–H) displayed matched para-OSCC and OSCC. (D, F, H) represented well, moderate, and poor differentiation of OSCC, respectively. Unannotated Scale bar = 100 μm. The Scale bar of the block tissue was 1mm. (I) decreased MUC21 expression level was related with cervical lymphatic metastasis and OSCC differentiation. “pN0” means no lymphatic metastasis, “pN1-PN3” referred to different degrees of lymphatic metastasis; “well +moderate” and “poor” referred to different degrees of differentiation.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing, Immunohistochemistry, Blocking Assay

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: Kaplan–Meier survival analyses for postoperative OSCC patients based on MUC21 expression. (A, B) Overall Survival (OS) and disease-free survival (DFS)with low MUC21 expression were significantly shorter than those with high MUC21 expression (P = 0.012 for OS, P<0.0001 for DFS). (C, D) , Forest map: The univariate analysis of OS and DFS in OSCC patients. (E, F) , Forest map: The multivariate analysis of OS and DFS in OSCC patients.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: In vitro cell lines experiment post overexpression and knockdown of MUC21. (A) MUC21 was significantly overexpressed and knocked down in CAL27 and HN6. (B) CCK-8 assay on CAL27 and HN6 post MUC21 manipulation. (C) Transwell assay without Matrigel coated filter of CAL27 and HN6 post MUC21 manipulation. (D) Transwell assay with Matrigel coated filter of CAL27 and HN6 post MUC21 manipulation. (E) wound-healing assay conducted at 24 hours post MUC21 manipulation in CAL27 and HN6 cells. NC: negative control, SH: MUC21 knockdown, OE: MUC21 overexpression. Statistical significance is denoted by *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: In Vitro, Over Expression, Knockdown, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Negative Control

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 1. Papanicolaou staining in liquid-based cytology (LBC) samples and BRD4, c-MYC, TP53, and MUC21 immunohistochemical study in oral cytological samples: (A) NILM, (B) LSIL, (C) HSIL, and (D) SCC. (E-H) BRD4 immunocytochemical staining. Although BRD4 staining was generally negative in (E) NILM samples, (F) positive nuclear staining was observed in LSIL, (G) HSIL, and (H) SCC samples. (I-L) c-MYC immunocytochemical staining. Although c-MYC staining was generally negative in (I) NILM samples, positive nuclear staining was observed in (J) LSIL, (K) HSIL, and (L) SCC samples. (M-P) TP53 immunocytochemical staining. Although TP53 staining was generally negative in (M) NILM, (N) LSIL, and (O) HSIL samples, positive nuclear staining was observed in (P) SCC samples. (Q-T) MUC21 immunocytochemical staining. Although MUC21 staining was generally positive in (M) NILM and (N) LSIL, negative cytoplasmic staining was observed in (O) HSIL and (T) SCC samples. Original magnification, 400 x. Scale bars, 20 µm. NILM, negative for intraepithelial lesion or malignancy; LSIL, low‑grade squamous intra epithelial lesion; HSIL, high‑grade squamous intraepithelial lesion; SCC, squamous cell carcinoma.

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques: Staining, Immunohistochemical staining

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 2. Histopathological and immunohistochemical expressions patterns of BRD4, c‑MYC, TP53, and MUC21 in normal epithelium (NOE), hyperplasia (HYP), oral epithelial dysplasia (OED), and squamous cell carcinoma (SCC) samples. (A, E, I, M, Q) NOE, (B, F, J, N, R) HYP, (C, G, K, O, S) OED and (D, H, L, P, T) SCC. (A-D) Hematoxylin and eosin (H&E), (E-H) BRD4, (I-L) c-MYC, (M-P) TP53, and (Q-T) MUC21. Original magnification, 100x. Scale bars, 100 µm.

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques: Immunohistochemical staining

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 4. The correlation between the labeling index and the relative mRNA levels of each marker (BRD4, c-MYC, TP53, and MUC21) in the oral cytological specimens. These markers displayed significant positive correlations: (A) BRD4 (R= 0.781, p < 0.01), (B) c‑MYC (R=0.807, p < 0.01), (C) TP53 (R=0.606, p < 0.01), and (D) MUC21 (R=0.514, p < 0.05).

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques: Labeling, Marker

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 5. Receiver operating characteristic analysis for LSIL or higher category specimens were screened using BRD4 (red line), c-MYC (green line), MUC21 (brown line), and TP53 (blue line) as candidate markers. The optimal cut-off values of each markers were calculated using ‘closest-topleft’ (10, 28).

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques:

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: Human MUC Gene Family Ordered by chromosomal location

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques: Expressing

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: Microarray analysis of impression cytology samples indicates that MUC20 is the most highly expressed mucin gene in human conjunctiva. n.d.: not detected. CD164 was previously designated as MUC24. MUC21 and MUC22 are not included in this analysis.

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques: Microarray

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: An anterior segment isolated from a human donor eye was formalin-fixed within 24-hours post-mortem and paraffin-embedded. A formalin-fixed human lacrimal gland embedded in paraffin was obtained from the Ophthalmic Pathology Laboratory of Tufts Medical Center. Tissues cross-sections were prepared, then processed and indirectly immunostained for MUC21 or MUC22 as described (Itakura et al., 2019). The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO). It is derived from a rabbit polyclonal antisera raised against a peptide from the human MUC21 cytoplasmic tail (561-CVRNSLSLRN TFNTAVYHPH GLNHGLGPGP GGNHGAPHRP RWSPNWFWRR PVSSIAMEMS GRNS-624), then affinity-purified. The human MUC22 primary antibody was characterized in one of our labs, as described (Hijikata et al., 2011). A rabbit polyclonal antisera produced by GENENET (Fukuoka, Japan) was raised against a peptide (TPTNVIKPSGYLQP) from the human MUC22 stem region located just before the transmembrane domain, then affinity-purified. A 3,3′-diaminobenzidine (DAB) chromogen kit was used to detect secondary antibody binding (Vector Laboratories, Burlingame, CA). The negative control (Neg. control) omitted the primary antibody. Sections were counterstained with hematoxylin. A-C) Cross-sections through the anterior segment focusing on immunostaining results (brown color) in the cornea epithelium. The hematoxylin counterstain is dark blue. Magnification = 40X. D-L) Cross-sections through the lacrimal showing immunostaining results (brown color). The hematoxylin counterstain is dark blue. D-F) Low magnification view (10X); G-I) Higher magnification (40X) focusing on a lacrimal duct; J-L) Higher magnification focusing on serous acini. These experimental findings have not been previously published.

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques: Isolation, Derivative Assay, Affinity Purification, Produced, Binding Assay, Plasmid Preparation, Negative Control, Immunostaining

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: Human Epithelial MAMs Ordered by Polypeptide Length

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques:

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: Conserved Motifs Found in Human MAMs Expressed at the Ocular Surface

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques:

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: Human Epithelial MAMs Ordered by Length of the CT

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques:

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: Comparison of Human and Mouse Epithelial MAM Genes Ordered by Human Chromosomal Locus

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques:

Journal: Progress in retinal and eye research

Article Title: Membrane-Associated Mucins of the Ocular Surface

doi: 10.1016/j.preteyeres.2019.100777

Figure Lengend Snippet: Comparison of Human and Mouse Epithelial MAMs Ordered by Human Protein Backbone Length

Article Snippet: The human MUC21 primary antibody was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

Techniques:

Journal: Experimental and Therapeutic Medicine

Article Title: MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

doi: 10.3892/etm.2022.11260

Figure Lengend Snippet: Relationship between MUC21 expression and clinicopathological characteristics of patients with glioblastoma (n=47).

Article Snippet: Slides were then incubated with MUC21 antibody (1:100; cat. no. NBP3-06591; Novus Biologicals, LLC) for 2 h at room temperature.

Techniques: Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

doi: 10.3892/etm.2022.11260

Figure Lengend Snippet: MUC21 is highly expressed in human GBM tissues. (A) A reverse transcription-quantitative PCR assay were conducted to determine the mRNA levels of MUC21 in GBM and corresponding adjacent non-cancerous tissues. A paired Student's t-test was used for the analysis of tumor and adjacent non-tumor samples. (B) Western blotting was performed to determine MUC21 expression in three GBM cell lines. (C) Immunohistochemistry was performed to evaluate the protein levels of MUC21 in GBM tumor and corresponding adjacent non-cancerous tissues. Magnification, x100 and x200 (scale bar, 5 mm). * P<0.05 as indicated. GBM glioblastoma; MUC21, mucin 21.

Article Snippet: Slides were then incubated with MUC21 antibody (1:100; cat. no. NBP3-06591; Novus Biologicals, LLC) for 2 h at room temperature.

Techniques: Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Expressing, Immunohistochemistry

Journal: Experimental and Therapeutic Medicine

Article Title: MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

doi: 10.3892/etm.2022.11260

Figure Lengend Snippet: MUC21 expression is downregulated in U251 and U87 cells after MUC21 shRNA transfection. (A) Reverse transcription-quantitative PCR assays were performed to measure MUC21 mRNA levels in U251 and U87 cells following control or MUC21 shRNA transfection. (B) Western blot analysis was performed to determine the protein expression of MUC21 in U251 and U87 cells following control or MUC21 shRNA transfection. * P<0.05 vs. shRNA. MUC21, mucin 21; NC, negative control; shRNA, short hairpin RNA.

Article Snippet: Slides were then incubated with MUC21 antibody (1:100; cat. no. NBP3-06591; Novus Biologicals, LLC) for 2 h at room temperature.

Techniques: Expressing, shRNA, Transfection, Reverse Transcription, Real-time Polymerase Chain Reaction, Control, Western Blot, Negative Control

Journal: Experimental and Therapeutic Medicine

Article Title: MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

doi: 10.3892/etm.2022.11260

Figure Lengend Snippet: MUC21 promotes GBM cell viability and migration in vitro . (A) Cell viability was assessed after MUC21 depletion in U87 and U251 through colony formation assays. (B) MTT assays were performed to detect the viability of cells transfected with the indicated shRNA. (C) Wound closure assay of GBM cells transfected with the indicated shRNA were performed for the quantification of migrated cells after 24 h. Magnification, x200. Western blotting assays were performed to analyze the expression of (D) Ki-67 and PCNA, and (E) MMP2 and MMP9 in GBM cells transfected with the indicated shRNA. Relative expression was analyzed. * P<0.05 and ** P<0.01 vs. the shNC group. GBM glioblastoma; MUC21, mucin 21; PCNA, proliferating cell nuclear antigen; shRNA, short hairpin RNA; NC, negative control.

Article Snippet: Slides were then incubated with MUC21 antibody (1:100; cat. no. NBP3-06591; Novus Biologicals, LLC) for 2 h at room temperature.

Techniques: Migration, In Vitro, Transfection, shRNA, Wound Closure Assay, Western Blot, Expressing, Negative Control

Journal: Experimental and Therapeutic Medicine

Article Title: MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

doi: 10.3892/etm.2022.11260

Figure Lengend Snippet: MUC21 contributes to GBM progression via the STAT3 and AKT signaling pathway. (A) The protein levels of p-STAT3, STAT3, p-AKT and AKT in shMUC21-transfected or control U251 cells were detected by immunoblot assays. (B) The protein levels of MUC21, p-STAT3, STAT3, p-AKT and AKT in MUC21-overexpressing or control U251 cells were detected by immunoblot assays. The relative expression was analyzed. * P<0.05 and ** P<0.01 vs. shNC or Con. Con, control; MUC21, mucin 21; NC, negative control; p-, phosphorylated; shRNA, short hairpin RNA.

Article Snippet: Slides were then incubated with MUC21 antibody (1:100; cat. no. NBP3-06591; Novus Biologicals, LLC) for 2 h at room temperature.

Techniques: Transfection, Control, Western Blot, Expressing, Negative Control, shRNA

Journal: Experimental and Therapeutic Medicine

Article Title: MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

doi: 10.3892/etm.2022.11260

Figure Lengend Snippet: MUC21 stimulates glioblastoma progression through the STAT3 and AKT pathway in vivo . (A) U251 cells stably transfected with control or MUC21 shRNA vectors were subcutaneously implanted into nude mice. Tumor volume was monitored every week. Isolated tumors were displayed in (A). Tumor growth curves were compared between control and MUC21 depletion groups. Murine weight was also measured. (B) An immunohistochemistry assay was conducted to assess MUC21 protein levels in control or MUC21-depleted groups (scale bar, 200 µm). (C) Western blotting assays were performed to assess the expression levels of the indicated proteins in control or MUC21-depleted tumor tissues isolated from nude mice. * P<0.05 and ** P<0.01 vs. shNC. MUC21, mucin 21; NC, negative control; PCNA, proliferating cell nuclear antigen; p-, phosphorylated; shRNA, short hairpin RNA.

Article Snippet: Slides were then incubated with MUC21 antibody (1:100; cat. no. NBP3-06591; Novus Biologicals, LLC) for 2 h at room temperature.

Techniques: In Vivo, Stable Transfection, Transfection, Control, shRNA, Isolation, Immunohistochemistry, Western Blot, Expressing, Negative Control